We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
Read MoreHide Full Article
Key Takeaways
RVTY posted Q4 adjusted EPS of $1.70, beating estimates, while revenue rose 5.9% year over year to $772.1M.
RVTY's Diagnostics segment drove growth with 10% revenue gains, while Life Sciences revenue was flat.
RVTY guided 2026 adjusted EPS of $5.35-$5.45 and revenues of $2.96-$2.99B, lifting shares premarket.
Revvity, Inc. (RVTY - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.70, which beat the Zacks Consensus Estimate of $1.63 by 4.3%. The bottom line improved 19.7% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 87 cents compared with 78 cents in the prior-year period.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $772.1 million, up 5.9% year over year and 4% organically. The top line was almost in line with the Zacks Consensus Estimate.
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $382 million, flat organically year over year.
Adjusted operating income amounted to $136 million, down 1.4% from the prior-year quarter’s figure.
Diagnostics
This segment’s revenues totaled $390 million, up 10% on a year-over-year basis. Organically, the top line increased 7% year over year.
Adjusted operating income amounted to $91 million, flat as compared with the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $251.7 million, up 3% year over year. Research and development expenses amounted to $58.2 million, up 18.2% from the year-ago quarter’s reported number.
Adjusted operating income declined 3.6% to $229.4 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 29.7%, contracting 60 basis points.
The company exited the fourth quarter of 2025 with cash and cash equivalents of $919.9 million compared with $931.4 million at the end of the prior quarter.
Cumulative net cash provided by operating activities totaled $582.9 million compared with $628.3 million in the year-ago quarter.
2026 Guidance
Revvity provided its earnings outlook and revenue guidance for 2026.
For 2026, the company expects adjusted EPS to be in the range of $5.35-$5.45. Revenues are anticipated to be in the band of $2.96-$2.99 billion. The Zacks Consensus Estimate for EPS and revenues is pegged at $5.32 and $2.94 billion, respectively.
Our Take
Revvity exited the fourth quarter of 2025 on a mixed note, wherein earnings beat estimates, but revenues were in line. Meanwhile, both the top and bottom lines improved year over year. The company provided its revenue and earnings outlook for 2026 with a projection reflecting organic growth of 2-3%.
Shares of RVTY gained 2.5% during pre-market trading following the mixed earnings result.
Revvity delivered a steady fourth-quarter and full-year 2025 performance, with both segments contributing in different ways. Life Sciences showed resilience, posting modest revenue growth despite a flat organic trend in the fourth quarter, reflecting a stable demand environment and disciplined execution. While margins softened slightly year over year, the segment continued to generate healthy operating income, underscoring the durability of its portfolio.
Diagnostics stood out on the top line, driven by strong quarterly momentum and solid organic growth for the year, even as adjusted margins came under pressure due to cost headwinds and mix. Taken together, the segment results highlight Revvity’s ability to balance growth and profitability across varied market conditions.
Boston Scientific shares have lost 12% in the past six months. Estimates for the company’s fourth-quarter 2025 EPS have remained constant at 78 cents in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.36%. In the last reported quarter, it posted an earnings surprise of 5.63%.
Estimates for Phibro Animal Health’s EPS for second-quarter fiscal 2026 have remained constant at 69 cents in the past 30 days. Shares of the company have risen 50.5% in the past six months compared with the industry’s 11.1% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.77%. In the last reported quarter, it delivered an earnings surprise of 23.73%.
AtriCure shares have risen 5.2% in the past six months. Estimates for the company’s fourth-quarter 2025 loss per share have remained stable at 4 cents in the past 30 days. ATRC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 67.06%. In the last reported quarter, it posted an earnings surprise of 90.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
Key Takeaways
Revvity, Inc. (RVTY - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.70, which beat the Zacks Consensus Estimate of $1.63 by 4.3%. The bottom line improved 19.7% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 87 cents compared with 78 cents in the prior-year period.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $772.1 million, up 5.9% year over year and 4% organically. The top line was almost in line with the Zacks Consensus Estimate.
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $382 million, flat organically year over year.
Adjusted operating income amounted to $136 million, down 1.4% from the prior-year quarter’s figure.
Diagnostics
This segment’s revenues totaled $390 million, up 10% on a year-over-year basis. Organically, the top line increased 7% year over year.
Adjusted operating income amounted to $91 million, flat as compared with the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $251.7 million, up 3% year over year. Research and development expenses amounted to $58.2 million, up 18.2% from the year-ago quarter’s reported number.
Adjusted operating income declined 3.6% to $229.4 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 29.7%, contracting 60 basis points.
Revvity Inc. Price, Consensus and EPS Surprise
Revvity Inc. price-consensus-eps-surprise-chart | Revvity Inc. Quote
Financial Update
The company exited the fourth quarter of 2025 with cash and cash equivalents of $919.9 million compared with $931.4 million at the end of the prior quarter.
Cumulative net cash provided by operating activities totaled $582.9 million compared with $628.3 million in the year-ago quarter.
2026 Guidance
Revvity provided its earnings outlook and revenue guidance for 2026.
For 2026, the company expects adjusted EPS to be in the range of $5.35-$5.45. Revenues are anticipated to be in the band of $2.96-$2.99 billion. The Zacks Consensus Estimate for EPS and revenues is pegged at $5.32 and $2.94 billion, respectively.
Our Take
Revvity exited the fourth quarter of 2025 on a mixed note, wherein earnings beat estimates, but revenues were in line. Meanwhile, both the top and bottom lines improved year over year. The company provided its revenue and earnings outlook for 2026 with a projection reflecting organic growth of 2-3%.
Shares of RVTY gained 2.5% during pre-market trading following the mixed earnings result.
Revvity delivered a steady fourth-quarter and full-year 2025 performance, with both segments contributing in different ways. Life Sciences showed resilience, posting modest revenue growth despite a flat organic trend in the fourth quarter, reflecting a stable demand environment and disciplined execution. While margins softened slightly year over year, the segment continued to generate healthy operating income, underscoring the durability of its portfolio.
Diagnostics stood out on the top line, driven by strong quarterly momentum and solid organic growth for the year, even as adjusted margins came under pressure due to cost headwinds and mix. Taken together, the segment results highlight Revvity’s ability to balance growth and profitability across varied market conditions.
RVTY’s Zacks Rank & Stocks to Consider
RVTY has a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Phibro Animal Health (PAHC - Free Report) and AtriCure (ATRC - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific shares have lost 12% in the past six months. Estimates for the company’s fourth-quarter 2025 EPS have remained constant at 78 cents in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.36%. In the last reported quarter, it posted an earnings surprise of 5.63%.
Estimates for Phibro Animal Health’s EPS for second-quarter fiscal 2026 have remained constant at 69 cents in the past 30 days. Shares of the company have risen 50.5% in the past six months compared with the industry’s 11.1% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.77%. In the last reported quarter, it delivered an earnings surprise of 23.73%.
AtriCure shares have risen 5.2% in the past six months. Estimates for the company’s fourth-quarter 2025 loss per share have remained stable at 4 cents in the past 30 days. ATRC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 67.06%. In the last reported quarter, it posted an earnings surprise of 90.91%.